Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1871 1
1887 1
1892 1
1932 1
1933 1
1934 1
1938 1
1939 1
1942 1
1943 1
1945 39
1946 27
1947 180
1948 206
1949 165
1950 448
1951 538
1952 628
1953 602
1954 609
1955 659
1956 582
1957 665
1958 583
1959 198
1960 2
1961 8
1962 9
1963 428
1964 620
1965 550
1966 552
1967 550
1968 559
1969 415
1970 331
1971 244
1972 187
1973 185
1974 161
1975 197
1976 229
1977 177
1978 220
1979 195
1980 167
1981 142
1982 140
1983 122
1984 161
1985 139
1986 117
1987 135
1988 186
1989 222
1990 225
1991 262
1992 217
1993 239
1994 214
1995 231
1996 221
1997 274
1998 291
1999 314
2000 392
2001 424
2002 453
2003 579
2004 625
2005 732
2006 927
2007 1067
2008 1251
2009 1286
2010 1502
2011 1605
2012 1811
2013 2052
2014 2806
2015 3296
2016 3712
2017 4013
2018 4364
2019 4818
2020 5787
2021 6128
2022 5295
2023 5117
2024 1944

Text availability

Article attribute

Article type

Publication date

Search Results

69,575 results

Results by year

Filters applied: . Clear all
The following term was not found in PubMed: Hoon-Ku
Page 1
Sulbactam-durlobactam: A novel β-lactam-β-lactamase inhibitor combination targeting carbapenem-resistant Acinetobacter baumannii infections.
El-Ghali A, Kunz Coyne AJ, Caniff K, Bleick C, Rybak MJ. El-Ghali A, et al. Pharmacotherapy. 2023 Jun;43(6):502-513. doi: 10.1002/phar.2802. Epub 2023 May 23. Pharmacotherapy. 2023. PMID: 37052117 Review.
The results of this trial demonstrated that SUL-DUR was non-inferior to colistin for CRAB while also possessing a much more favorable safety profile. SUL-DUR was well-tolerated with the most common side effects being headache, nausea, and injection-site phlebitis. . …
The results of this trial demonstrated that SUL-DUR was non-inferior to colistin for CRAB while also possessing a much more favorable …
CRÍTICA À ABORDAGEM DE PESQUISA E USO DO IRAMUTEQ.
Amaral-Rosa MP, Báo ACP. Amaral-Rosa MP, et al. Rev Bras Enferm. 2022 Jul 8;75(6):e2022750603c. doi: 10.1590/0034-7167.2022750603c. Rev Bras Enferm. 2022. PMID: 35830092 Free PMC article. Portuguese. No abstract available.
Sodium-Polystyrene Sulfonate-Induced Colitis.
Dos Santos FS, Aver GP, Paim TV, Riva F, Brambilla E, Soldera J. Dos Santos FS, et al. GE Port J Gastroenterol. 2021 Dec 14;30(2):153-155. doi: 10.1159/000521195. eCollection 2023 Mar. GE Port J Gastroenterol. 2021. PMID: 37008520 Free PMC article. No abstract available.
Pathology in Practice.
Henker LC, Dal Pont TP, Santos IR, Bettim Bandinelli M, Brito EL, Trein CR, Pavarini SP, Driemeier D. Henker LC, et al. J Am Vet Med Assoc. 2022 May 18;259(S2):1-3. doi: 10.2460/javma.21.03.0143. J Am Vet Med Assoc. 2022. PMID: 35576183 Free article.
Cannabidiol (CBD): Potential Use in Otorhinolaryngology.
Jotz GP, Ortiz RS, Limberger RP, de Oliveira Camargo FA. Jotz GP, et al. Int Arch Otorhinolaryngol. 2024 Feb 5;28(1):e1-e2. doi: 10.1055/s-0043-1777857. eCollection 2024 Jan. Int Arch Otorhinolaryngol. 2024. PMID: 38322448 Free PMC article. No abstract available.
Sulbactam-Durlobactam in the Treatment of Carbapenem-Resistant Acinetobacter baumannii Infections.
August B, Matlob A, Kale-Pradhan PB. August B, et al. Ann Pharmacother. 2023 Oct 10:10600280231204566. doi: 10.1177/10600280231204566. Online ahead of print. Ann Pharmacother. 2023. PMID: 37817550 Review.
Overall treatment success in the microbiological intention-to-treat analysis was reported in 76.6% of patients in the SUL-DUR group compared with 81% patients in the placebo group. A phase III trial compared SUL-DUR with colistin in adults with confirmed CRAB infect …
Overall treatment success in the microbiological intention-to-treat analysis was reported in 76.6% of patients in the SUL-DUR group c …
The Novel Compound SUL-138 Counteracts Endothelial Cell and Kidney Dysfunction in Sepsis by Preserving Mitochondrial Function.
Star BS, van der Slikke EC, van Buiten A, Henning RH, Bouma HR. Star BS, et al. Int J Mol Sci. 2023 Mar 28;24(7):6330. doi: 10.3390/ijms24076330. Int J Mol Sci. 2023. PMID: 37047303 Free PMC article.
Further, SUL-138 dampened the LPS-induced expression of IL-1beta, but not of NLRP3, and IL-18 in HUVECs. Sepsis in mice induced by cecal ligation and puncture (CLP) led to a lower mitochondrial membrane potential and increased levels of mitochondrial oxidative stress in th …
Further, SUL-138 dampened the LPS-induced expression of IL-1beta, but not of NLRP3, and IL-18 in HUVECs. Sepsis in mice induced by ce …
Plants with Anti-Addictive Potential.
Konrath EL, Arbo MD, Arbo BD, Hort MA, Elisabetsky E, Leal MB. Konrath EL, et al. Adv Exp Med Biol. 2021;1308:185-215. doi: 10.1007/978-3-030-64872-5_14. Adv Exp Med Biol. 2021. PMID: 33861445
Pathogen-Targeted Clinical Development to Address Unmet Medical Need: Design, Safety, and Efficacy of the ATTACK Trial.
Watkins RR, Du B, Isaacs R, Altarac D. Watkins RR, et al. Clin Infect Dis. 2023 May 1;76(Suppl 2):S210-S214. doi: 10.1093/cid/ciad097. Clin Infect Dis. 2023. PMID: 37125468 Free PMC article. Clinical Trial.
The development of SUL-DUR culminated with the Acinetobacter Treatment Trial Against Colistin (ATTACK) trial, a global, randomized, active-controlled phase 3 clinical trial that compared SUL-DUR with colistin for treating serious infections due to carbapenem-resista …
The development of SUL-DUR culminated with the Acinetobacter Treatment Trial Against Colistin (ATTACK) trial, a global, randomized, a …
69,575 results
You have reached the last available page of results. Please see the User Guide for more information.